文献速递神经肿瘤

神经与知识专家推理混合智能用于SRS(THINKERS):脑膜瘤AI模型

Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS (THINKERS): an AI model for meningioma.
PubMed 文献 · J Neurooncol · 2026-07-17

本研究开发了THINKERS-Meningioma混合专家人工智能框架,用于脑膜瘤立体定向放射外科治疗后个体化剂量评估。回顾性单中心800例患者数据训练离散时间生存模型,内部验证5年局部进展AUC为0.861±0.088,留出集校准AUC为0.861(95%CI 0.829-0.915)。

要点

  • THINKERS-Meningioma可个体化预测脑膜瘤SRS后5年局部进展。
  • 边缘剂量作为可查询输入,支持重复候选剂量评估。
  • 交叉验证校准AUC 0.861±0.088,留出集校准AUC 0.861。

核心结论

  • THINKERS-Meningioma为脑膜瘤SRS后个体化5年局部进展预测和剂量策略评估提供了内部验证框架。

研究设计与样本

  • 回顾性单中心研究,纳入800例接受立体定向放射外科治疗的颅内脑膜瘤患者。
  • 使用治疗前或治疗时可用变量训练混合专家神经网络,结合离散时间生存建模。
  • 内部验证采用分层5折交叉验证和分层留出测试集。

主要发现

  • 交叉验证中,5年局部肿瘤进展的原始平均AUC为0.854±0.077,校准后平均AUC为0.861±0.088。
  • 交叉验证原始和校准Brier分数分别为0.0021±0.0020和0.0016±0.0024。
  • 交叉验证MAE为1.67±0.20个月。
  • 分层留出集中,原始AUC为0.841,校准AUC为0.861(95%CI 0.829-0.915)。
  • 留出集预期局部进展时间的MAE为1.71个月(95%CI 1.00-2.01)。

临床怎么用

  • 该模型可用于脑膜瘤SRS后个体化5年局部进展预测,并支持候选剂量方案的重复评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prescription dose selection for intracranial meningiomas treated with stereotactic radiosurgery remains guided by tumor volume, anatomical constraints, proximity to critical structures, and institutional practice rather than individualized estimates of long-term local progression. We developed THINKERS-Meningioma, a mixture-of-experts artificial intelligence framework for personalized dose evaluation after stereotactic radiosurgery. METHODS: We performed a retrospective single-center study of 800 patients with intracranial meningiomas treated with stereotactic radiosurgery. Variables available before or at treatment were used to train a mixture-of-experts neural network with discrete-time survival modeling. Margin dose was incorporated as a queryable input to enable repeated candidate dose evaluation. Internal validation used stratified 5-fold cross-validation and a stratified holdout test split. Performance was assessed using area under the receiver operating characteristic curve (AUC) for 5-year local tumor progression, mean absolute error (MAE) for expected time to local progression, Brier score, and calibration metrics. RESULTS: In stratified cross-validation, THINKERS-Meningioma achieved a raw mean AUC of 0.854 ± 0.077 and calibrated mean AUC of 0.861 ± 0.088 for 5-year local tumor progression. Raw and calibrated Brier scores were 0.0021 ± 0.0020 and 0.0016 ± 0.0024, respectively. The cross-validation MAE was 1.67 ± 0.20 months. In the stratified holdout set, raw AUC was 0.841 and calibrated AUC was 0.861 (95% CI, 0.829-0.915). MAE for expected time to local progression was 1.71 months (95% CI, 1.00-2.01). CONCLUSIONS: THINKERS-Meningioma provides an internally validated framework for individualized 5-year local progression prediction and dose-policy evaluation after stereotactic radiosurgery for intracranial meningiomas. CLINICAL TRIAL NUMBER: Not applicable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Reyes JS, Niranjan A, Bouras A, et al. Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS (THINKERS): an AI model for meningioma. J Neurooncol. 2026. PMID: 42467105. doi:10.1007/s11060-026-05719-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。